Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
Trial · NCT03296800
Results by group66
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 66
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cmax (Maximum Observed Plasma Concentration) | Study 1: Bexagliflozin Alone | 161.675 | Geometric Coefficient of Variation 28.673 | ng/mL | |
| Cmax (Maximum Observed Plasma Concentration) | Study 1: Bexagliflozin and Probenecid | 193.366 | Geometric Coefficient of Variation 22.098 | ng/mL | |
| Cmax (Maximum Observed Plasma Concentration) | Study 2: Bexagliflozin Alone | 97.811 | Geometric Coefficient of Variation 53.903 | ng/mL | |
| Cmax (Maximum Observed Plasma Concentration) | Study 2: Bexagliflozin and Rifampin | 117.001 | Geometric Coefficient of Variation 60.097 | ng/mL | |
| Cmax (Maximum Observed Plasma Concentration) | Study 3: Bexagliflozin Alone | 159.355 | Geometric Coefficient of Variation 35.396 | ng/mL | |
| Cmax (Maximum Observed Plasma Concentration) | Study 3: Bexagliflozin and Verapamil | 169.000 | Geometric Coefficient of Variation 24.727 | ng/mL | |
| Tmax (Time of Maximum Observed Plasma Concentration) | Bexagliflozin/Probenecid | Bexagliflozin alone | 2.000 | Full Range 2.000 to 4.000 | hours |
| Tmax (Time of Maximum Observed Plasma Concentration) | Bexagliflozin/Rifampin | Bexagliflozin alone | 2.000 | Full Range 2.000 to 4.083 | hours |
| Tmax (Time of Maximum Observed Plasma Concentration) | Bexagliflozin/Verapamil | Bexagliflozin alone | 3.0 | Full Range 2.000 to 8.000 | hours |
| Tmax (Time of Maximum Observed Plasma Concentration) | Bexagliflozin/Probenecid | Bexagliflozin + additional drug | 3.000 | Full Range 2.000 to 4.017 | hours |
| Tmax (Time of Maximum Observed Plasma Concentration) | Bexagliflozin/Rifampin | Bexagliflozin + additional drug | 2.000 | Full Range 1.017 to 4.000 | hours |
| Tmax (Time of Maximum Observed Plasma Concentration) | Bexagliflozin/Verapamil | Bexagliflozin + additional drug | 3.000 | Full Range 2.000 to 4.000 | hours |
| T1/2 (Apparent Terminal Elimination Half-life) | Bexagliflozin/Probenecid | Bexagliflozin alone | 12.090 | Geometric Coefficient of Variation 35.950 | hours |
| T1/2 (Apparent Terminal Elimination Half-life) | Bexagliflozin/Rifampin | Bexagliflozin alone | 12.190 | Geometric Coefficient of Variation 36.966 | hours |
| T1/2 (Apparent Terminal Elimination Half-life) | Bexagliflozin/Verapamil | Bexagliflozin alone | 10.709 | Geometric Coefficient of Variation 44.103 | hours |
| T1/2 (Apparent Terminal Elimination Half-life) | Bexagliflozin/Probenecid | Bexagliflozin + additional drug | 13.894 | Geometric Coefficient of Variation 24.806 | hours |
| T1/2 (Apparent Terminal Elimination Half-life) | Bexagliflozin/Rifampin | Bexagliflozin + additional drug | 5.318 | Geometric Coefficient of Variation 49.740 | hours |
| T1/2 (Apparent Terminal Elimination Half-life) | Bexagliflozin/Verapamil | Bexagliflozin + additional drug | 11.675 | Geometric Coefficient of Variation 48.222 | hours |
| AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity) | Study 1: Bexagliflozin Alone | 1118.741 | Geometric Coefficient of Variation 23.290 | hr*ng/mL | |
| AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity) | Study 1: Bexagliflozin/Probenecid | 1583.188 | Geometric Coefficient of Variation 23.676 | hr*ng/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03296800/results